Celgene (CELG) is rising on Thursday, on the heels of its mixed first quarter earnings report.
F. Martin Ramin for WSJ. Magazine, Styling by Anne Cardenas
Celgene said it earned $1.32 a share on revenue of $2.51 billion. Analysts were looking for earnings of $1.27 a share on revenue of $2.58 billion.
For the full year, the company said it expects to earn between $5.60 and $5.70 a share, compared to the $5.68 consensus estimate. For fiscal 2017, it lowered its forecast, saying it now expects to earn between $6.75 and $7 a share (from a previous $7.25), compared to the $7.21 consensus.
Raymond Jamess Christopher Raymond reiterated a Strong Buy rating; he writes that the lower 2017 guidance wasnt really a surprise, and the 2020 numbers still look encouraging:
Recall, management had suggested a 2017 guidance update would arrive at the 1Q16 call, with an ~$800 million FX headwind that has surfaced since its original issuance. Today, FY17 product revenue guidance was lowered to $12.7-13.0 billion (previously $13-14 billion), which brackets pre-existing FY17 consensus of $12.954 billion. Revlimid net sales moves up $1 billion to $8 billion and Abraxane was lowered to $1 billion (previously $1.5-2.0 billion). Non-GAAP EPS moves to $6.75-7.00 from $7.25 (consensus $7.20). Separately, 2020 targets remain in place. Bottom line, the guidance update should surprise few in our view, and will likely be seen as a clearing event.
Best Rising Stocks To Buy For 2016: Biogen Idec Inc(BIIB)
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t h e treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
- [By Ben Levisohn]
On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:
Best Rising Stocks To Buy For 2016: Kinder Morgan, Inc.(KMI)
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments. The Natural Gas Pipelines segment owns and operates interstate and intrastate natural gas pipeline and storage systems; natural gas and crude oil gathering systems, and natural gas processing and treating facilities; and natural gas liquids fractionation facilities and transportation systems. The CO2 segment produces, transports, and markets CO2 for use in enhanced oil recovery projects; and owns interest in oil-producing fields, gas processing plants, and crude oil pipelines located in the Permian Basin region of West Texas. The Terminals segment owns and operates liquids and bulk terminals, and rail transloading and materials handling facilities that transload and store refined petroleum products; crude o il; condensate; and bulk products, including coal, petroleum coke, cement, alumina, salt, and other bulk chemicals, as well as owns and operates seven tankers. The Products Pipelines segment owns and operates refined petroleum products, and crude oil and condensate pipelines; and associated product terminals and petroleum pipeline transmix facilities. The Kinder Morgan Canada segment owns and operates Trans Mountain pipeline system that transports crude oil and refined petroleum products from Edmonton, Alberta, and Canada to marketing terminals and refineries in British Columbia, Canada, and Washington State; and aviation turbine fuel pipeline. The Other segment includes various physical natural gas contracts with power plants. Kinder Morgan, Inc. owns an interest in or operates approximately 80,000 miles of pipelines and 180 terminals. The company was formerly known as Kinder Morgan Holdco LLC and changed its name to Kinder Morgan, Inc. in February 2011. Kinder Morgan, Inc. was founded in 1936 and is headquartered in Houston, Texas.!
- [By Roberto Pedone]
One energy player that insiders are buying up a huge amount of stock in here is Kinder Morgan (KMI), which owns interests in an energy transportation and storage company. Insiders are buying this stock into modest strength, since shares are up 2.4% so far in 2013.
Kinder Morgan has a market cap of $37.5 billion and an enterprise value of $71 billion. This stock trades at a premium valuation, with a trailing price-to-earnings of 37.94 and a forward price-to-earnings of 23.03. Its estimated growth rate for this year is 153.1%, and for next year it’s pegged at 26.6%. This is not a cash-rich company, since the total cash position on its balance sheet is $1.02 billion and its total debt is a whopping $35.60 billion. This stock currently sports a dividend yield of 4.2%
The CEO and chairman of the board just bought 500,000 shares, or about $17.86 million worth of stock, at $35.74 a share.
From a technical perspective, KMI is currently trending below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending for the last two months, with shares moving lower from its July high of $40.03 a share to its recent low of $34.82 a share. During that downtrend, shares of KMI have been making mostly lower highs and lower lows, which is bearish technical price action.
If you’re bullish on KMI, then I would look for long-biased trades as long as this stock is trending above its 200-day at $36.97, and then once takes out some near-term overhead resistance levels at 50-day at $37.80 a share to more resistance at $38.29 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 4.91 million shares. If we get that move soon, then KMI will set up to re-test or possibly take out its next major overhead resistance levels at $40.03 to $41.06 a share.
- [By Dimitra DeFotis]
In a nutshell: Hedgeye says investors should worry more about Kinder’s pipeline maintenance and spending therein. And it says Kinder’s exploration and production business, while small, is NOT a pipeline enterprise and valuation should reflect that.Moreover, Hedgeye says it thinks Kinder Morgans strategy is to “starve its pipelines and related infrastructure of routine maintenance spending” so that it can maximize distributable cash flow and payments to the general partner, Kinder Morgan(KMI). As a structure,MLPs pay out most of their cash flow as tax-deferred distributions to investors in their “units,” as shares are called.
- [By Ben Levisohn]
Kinder Morgan (KMI) fell 2.8% to $36.01 today, one day after Hedgeye released its report on the company.
PVH (PVH) dropped 1.5% to $22.80, a day after falling 5.6% on disappointing earnings, after a Citigroup analyst said its no longer one of her top picks.
Hot Prefered Companies To Own For 2016: Whiting Petroleum Corporation(WLL)
Whiting Petroleum Corporation engages in the acquisition, development, exploitation, exploration, and production of oil and gas primarily in the Permian Basin, Rocky Mountains, Mid-Continent, Gulf Coast, and Michigan regions of the United States. As of December 31, 2010, its estimated proved reserves were 304.9 million barrels equivalent of oil; and had interests in 9,698 gross productive wells covering approximately 1,115,000 gross developed acres. The company sells its oil and gas to end users, marketers, and other purchasers. Whiting Petroleum Corporation was founded in 1983 and is Denver, Colorado.
- [By Andrew Efimoff]
WTI crude oil plunged 3.11 percent on Friday to $48.99 a barrel. Below are the biggest energy losers for the day:
California Resources Corporation (NYSE: CRC): -19.22% Dynamic Materials (NASDAQ: BOOM): -12.39% Clayton Williams Energy (NYSE: CWEI): -11.45% Dynergy (NYSE: DYN): -11.91% EP Energy Corporation (NYSE: EPE): -11.20% Mexco Energy (NYSE: MXC) -10.90% Whiting Petroleum (NYSE: WLL) -10.79% Southwestern Energy Company (NYSE: SWN) -10.79% SM Energy Company (NYSE: SM) -10.38% Real Goods Solar (NASDAQ: RGSE) -10.34%
Posted-In: Commodities After-Hours Center Markets Movers
- [By Lisa Levin]
Energy shares surged around 1.85 percent in trading on Monday. Top gainers in the sector included Legacy Reserves LP (NASDAQ: LGCY), Whiting Petroleum Corp (NYSE: WLL), and Atwood Oceanics, Inc. (NYSE: ATW).
Best Rising Stocks To Buy For 2016: Alimera Sciences, Inc.(ALIM)
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, Portugal, and the United Kingdom. The company focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patients eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a constant micro-dose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. It has license agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and pr evention of eye diseases in humans (other than uveitis) or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
- [By Lisa Levin]
On Thursday, the healthcare sector proved to be a source of strength for the market. Leading the sector was strength from Alimera Sciences Inc (NASDAQ: ALIM) and Anthera Pharmaceuticals Inc (NASDAQ: ANTH).
- [By Lisa Levin]
Alimera Sciences Inc (NASDAQ: ALIM) shares shot up 59 percent to $1.69 after the company reported preliminary Q2 revenue. Alimera Sciences announced preliminary revenue of $9.3 million to $9.5 million.
Best Rising Stocks To Buy For 2016: MPLX LP(MPLX)
MPLX LP owns, operates, develops, and acquires pipelines and other midstream assets related to the transportation and storage of crude oil, refined product, and other hydrocarbon-based products in the United States. As of December 31, 2014, the company owned a 99.5% interest in an entity, which in turn collectively owned and operated a network of pipeline systems that include approximately 1,004 miles of common carrier crude oil pipelines; and approximately 1,902 miles of common carrier product pipelines in 9 states. It also holds a 100% interest in butane cavern located in Neal, West Virginia with approximately 1 million barrels of storage capacity. In addition, the company operates crude oil and product pipelines owned by third parties. MPLX GP LLC acts as the general partner of MPLX LP. The company was founded in 2012 and is headquartered in Findlay, Ohio. MPLX LP is a subsidiary of Marathon Petroleum Corporation.
- [By Ben Levisohn]
JPMorgan analyst Phil Gresh and team explain what they got wrong about Marathon Petroleum (MPC), as they cut its rating to Neutral from Overweight following yesterday’s disastrous financial results from MPLX (MPLX):
- [By Garrett Cook]
Lastly, Citi says Marathon Petroleum (NYSE: MPC) and MPLX LP (NYSE: MPLX) remain Buy rated the heels of benefits derived from strong product demand and the NGL recovery.